JP7535993B2 - メタロ－リオサイロニン - Google Patents

メタロ－リオサイロニン Download PDF

Info

Publication number
JP7535993B2
JP7535993B2 JP2021503706A JP2021503706A JP7535993B2 JP 7535993 B2 JP7535993 B2 JP 7535993B2 JP 2021503706 A JP2021503706 A JP 2021503706A JP 2021503706 A JP2021503706 A JP 2021503706A JP 7535993 B2 JP7535993 B2 JP 7535993B2
Authority
JP
Japan
Prior art keywords
complex
biologically active
triiodothyronine
metal
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021503706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521268A (ja
JPWO2019195513A5 (de
Inventor
プライス，ジョン，ディー．
ピカリエッロ，トーマス
マルヘア，ミカエラ，イー．
Original Assignee
シンソニクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンソニクス，インコーポレイテッド filed Critical シンソニクス，インコーポレイテッド
Publication of JP2021521268A publication Critical patent/JP2021521268A/ja
Publication of JPWO2019195513A5 publication Critical patent/JPWO2019195513A5/ja
Application granted granted Critical
Publication of JP7535993B2 publication Critical patent/JP7535993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
JP2021503706A 2018-04-04 2019-04-04 メタロ－リオサイロニン Active JP7535993B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652705P 2018-04-04 2018-04-04
US62/652,705 2018-04-04
PCT/US2019/025725 WO2019195513A1 (en) 2018-04-04 2019-04-04 Metallo-liothyronine

Publications (3)

Publication Number Publication Date
JP2021521268A JP2021521268A (ja) 2021-08-26
JPWO2019195513A5 JPWO2019195513A5 (de) 2022-04-27
JP7535993B2 true JP7535993B2 (ja) 2024-08-19

Family

ID=68101148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503706A Active JP7535993B2 (ja) 2018-04-04 2019-04-04 メタロ－リオサイロニン

Country Status (9)

Country Link
US (2) US11712426B2 (de)
EP (1) EP3773733B1 (de)
JP (1) JP7535993B2 (de)
KR (1) KR20200143701A (de)
CN (1) CN112218661A (de)
AU (1) AU2019247217A1 (de)
BR (1) BR112020020403A8 (de)
CA (1) CA3096199A1 (de)
WO (1) WO2019195513A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7535993B2 (ja) * 2018-04-04 2024-08-19 シンソニクス，インコーポレイテッド メタロ－リオサイロニン
JP2022030705A (ja) * 2020-08-07 2022-02-18 日本曹達株式会社 チアベンダゾール含有配位高分子

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506049A (ja) 1998-03-10 2002-02-26 ブラッコ エッセ ピ ア 血清中で高い緩和性を有するマンガンキレート
JP2003261683A (ja) 2002-03-06 2003-09-19 Nof Corp 中性（ベンゼン−１，２，４，５−テトラチオラート）金属錯体ポリマー、その製造方法および用途
WO2007099932A1 (ja) 2006-03-02 2007-09-07 Inter-University Research Institute Corporation National Institutes Of Natural Sciences マイクロチャンネルリアクター
JP2009512728A (ja) 2005-10-24 2009-03-26 シントニクス，インコーポレーテッド 金属配位組成物
JP2013542961A (ja) 2010-11-08 2013-11-28 シンソニックス、インク． 生理活性物質の性質を調節するビスマス含有化合物
WO2015167010A1 (ja) 2014-05-02 2015-11-05 国立研究開発法人物質・材料研究機構 有機／ヘテロ金属ハイブリットポリマー、その製造方法、有機／ヘテロ金属ハイブリットポリマーの膜、有機／マルチ金属ハイブリットポリマー、その製造方法、及び有機／マルチ金属ハイブリットポリマーの膜
JP2017079181A (ja) 2015-10-21 2017-04-27 コニカミノルタ株式会社 光変換材料、光変換フィルム、及び発光素子

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799937B2 (en) * 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
AU2013205471B2 (en) 2005-10-24 2016-02-11 Synthonics, Inc. Metal coordinated compositions
EP2536408A1 (de) * 2010-02-16 2012-12-26 Wockhardt Research Centre Effluxpumpenhemmer
AU2015277509A1 (en) 2014-06-18 2017-01-05 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
JP7535993B2 (ja) * 2018-04-04 2024-08-19 シンソニクス，インコーポレイテッド メタロ－リオサイロニン

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506049A (ja) 1998-03-10 2002-02-26 ブラッコ エッセ ピ ア 血清中で高い緩和性を有するマンガンキレート
JP2003261683A (ja) 2002-03-06 2003-09-19 Nof Corp 中性（ベンゼン−１，２，４，５−テトラチオラート）金属錯体ポリマー、その製造方法および用途
JP2009512728A (ja) 2005-10-24 2009-03-26 シントニクス，インコーポレーテッド 金属配位組成物
WO2007099932A1 (ja) 2006-03-02 2007-09-07 Inter-University Research Institute Corporation National Institutes Of Natural Sciences マイクロチャンネルリアクター
JP2013542961A (ja) 2010-11-08 2013-11-28 シンソニックス、インク． 生理活性物質の性質を調節するビスマス含有化合物
WO2015167010A1 (ja) 2014-05-02 2015-11-05 国立研究開発法人物質・材料研究機構 有機／ヘテロ金属ハイブリットポリマー、その製造方法、有機／ヘテロ金属ハイブリットポリマーの膜、有機／マルチ金属ハイブリットポリマー、その製造方法、及び有機／マルチ金属ハイブリットポリマーの膜
JP2017079181A (ja) 2015-10-21 2017-04-27 コニカミノルタ株式会社 光変換材料、光変換フィルム、及び発光素子

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARRAHER. C. E. et al.，degradation of the polyamine derived from tetrachloroplatinate and methotrexate，POLYMERIC MATERIALS SCIENCE AND ENGINEERING，1987年，Vol.57，pp.173-176
CHARRAHER, C. E. Jr. and ZHAO, A.，Modeling of moderate mass range F MALDI MS results of organotin poly(ester amines) derived frm ciprofloacin and dibutyltin dichloride，PMSE Preprints，2011年，Vol.106
MARINEZ, V. R. et al.，Azilsartan and its Zn(II) complex. Synthesis, anticancer mechanisms of action and binding to bovine serum albumin，Toxicology in Vitro，2018年03月06日，Vol.48，pp.205-220，DOI:10.1016/j.tiv.2018.01.009
RODRIGO R. DA CONCEICAO; ET AL，METAL COORDINATED POLY-ZINC-LIOTHYRONINE PROVIDES STABLE CIRCULATING TRIIODOTHYRONINE LEVELS IN HYPOTHYROID RATS，THYROID，2018年11月12日，VOL.28, ISSUE.11，PAGE(S):1425-1433，https://www.liebertpub.com/doi/10.1089/thy.2018.0205
ZHAO, A.and CARRAHER, C. E. Jr.，F MALDI MS for polymers from ciprofloxacin and organotin dihalides，PMSE PREPRINTS，2007年，Vol.96，pp.390-392

Also Published As

Publication number Publication date
JP2021521268A (ja) 2021-08-26
US20230381126A1 (en) 2023-11-30
EP3773733A1 (de) 2021-02-17
EP3773733B1 (de) 2025-11-12
BR112020020403A8 (pt) 2021-04-13
WO2019195513A1 (en) 2019-10-10
US20210046032A1 (en) 2021-02-18
US11712426B2 (en) 2023-08-01
KR20200143701A (ko) 2020-12-24
EP3773733C0 (de) 2025-11-12
EP3773733A4 (de) 2022-05-25
CN112218661A (zh) 2021-01-12
AU2019247217A1 (en) 2020-11-26
CA3096199A1 (en) 2019-10-10
BR112020020403A2 (pt) 2021-03-23

Similar Documents

Publication Publication Date Title
AU2010278860B2 (en) Crystallization method and bioavailability
DK2531200T3 (en) COSTALLIZATION PROCEDURE AND BIOTA ACCESSIBILITY
US20230381126A1 (en) Metallo-liothyronine
JP2007530737A (ja) 架橋アミンポリマー
CZ43995A3 (en) Cross-linked polymeric ammonium salt, its use in the preparation of a medicament and a pharmaceutical composition containing such salt
US9402861B2 (en) Polyamine-dihydroxybenzoic acid conjugate hydrogels as iron chelators
KR20000067929A (ko) 고인혈증 치료제
CA2658338A1 (en) Amine dendrimers
JP2001503457A (ja) 食物ホスフェート又はオキサレート吸収を低下させるための水溶性ポリマー
AU2014219129A1 (en) Caged platinum nanoclusters for anticancer chemotherapeutics
CN106581683A (zh) 一种聚乙二醇修饰的金属有机纳米材料及其制备方法、应用
WO2017208070A1 (en) Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
Smith Polymeric Chelators For Pharmaceutical Applications
M’bitsi-Ibouily Design and evaluation of metal-liganded bioactive delivery system for enhanced oral bioavailability
HK1171966B (en) Crystallization method and bioavailability
HK1171966A (en) Crystallization method and bioavailability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240806

R150 Certificate of patent or registration of utility model

Ref document number: 7535993

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150